237 related articles for article (PubMed ID: 16337868)
1. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Ossard-Receveur A; Bernheim A; Clausse B; Danglot G; Fauvet D; Leon B; Lozach F; Bories D; Brouzes C; Bourhis JH; Turhan AG
Cancer Genet Cytogenet; 2005 Dec; 163(2):189-90. PubMed ID: 16337868
[No Abstract] [Full Text] [Related]
2. Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
Szych CM; Liesveld JL; Iqbal MA; Li L; Siebert S; Asmus C; O'Malley J; Lee A; Wang N
Cancer Genet Cytogenet; 2007 Apr; 174(2):132-7. PubMed ID: 17452255
[TBL] [Abstract][Full Text] [Related]
3. Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003.
Marcucci G; Perrotti D; Caligiuri MA
Clin Cancer Res; 2003 Apr; 9(4):1248-52. PubMed ID: 12684391
[No Abstract] [Full Text] [Related]
4. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
5. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
6. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Espinet B; Oliveira AC; Boqué C; Domingo A; Alonso E; Solé F
Haematologica; 2005 Apr; 90(4):556-8. PubMed ID: 15820956
[TBL] [Abstract][Full Text] [Related]
7. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
Rowe LR; Brothman AR; Nibley WE; Gaffney MR; Chen Z
Cancer Genet Cytogenet; 2007 Apr; 174(1):54-6. PubMed ID: 17350467
[TBL] [Abstract][Full Text] [Related]
8. [STI571: the resistance organizes!].
Jeanteur P
Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
[No Abstract] [Full Text] [Related]
9. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
[No Abstract] [Full Text] [Related]
10. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Drummond MW; Holyoake TL
Cancer; 2003 Oct; 98(8):1776-7; author reply 1777-8. PubMed ID: 14534900
[No Abstract] [Full Text] [Related]
11. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
12. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
[No Abstract] [Full Text] [Related]
13. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
[TBL] [Abstract][Full Text] [Related]
14. Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Richardson MW; Grewal SS
Pediatr Blood Cancer; 2008 Jan; 50(1):186. PubMed ID: 17455313
[No Abstract] [Full Text] [Related]
15. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission.
Cherrier-De Wilde S; Rack K; Vannuffel P; Delannoy A; Hagemeijer A
Leukemia; 2003 Oct; 17(10):2046-8. PubMed ID: 14513056
[No Abstract] [Full Text] [Related]
16. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
17. [Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Chen SS
Zhonghua Xue Ye Xue Za Zhi; 2006 Jul; 27(7):433-5. PubMed ID: 17147242
[No Abstract] [Full Text] [Related]
18. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Kantarjian H; O'Brien S; Talpaz M; Borthakur G; Ravandi F; Faderl S; Verstovsek S; Rios MB; Shan J; Giles F; Cortes J
Cancer; 2007 Apr; 109(8):1556-60. PubMed ID: 17342766
[TBL] [Abstract][Full Text] [Related]
19. Update on the use of imatinib mesylate.
Sawyers CL
Clin Adv Hematol Oncol; 2005 Oct; 3(10):757-8. PubMed ID: 16258483
[No Abstract] [Full Text] [Related]
20. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
Tauchi T; Oyashiki K
Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
[No Abstract] [Full Text] [Related]
[Next] [New Search]
